21IN - Targeting of the LXR-cholesterol axis as a metabolic co-dependency for brain cancers

Date 06 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Metabolic targets
Topics Biomarkers
Central Nervous System Malignancies
Translational Research
Presenter Genaro Villa
Citation Annals of Oncology (2018) 29 (suppl_3): iii1-iii6. 10.1093/annonc/mdy046
Authors G. Villa
  • -, UCLA - School of Medicine, 90095 - Los Angeles/US


Oncogenic mutations in growth factor receptor signaling pathways are common in cancer, including in tumors that arise from or metastasize to the brain. However, most small-molecule inhibitors targeting growth factor receptors have failed to show efficacy for brain cancers, potentially due to inability to achieve sufficient drug levels in the central nervous system (CNS). Targeting tumor co-dependencies provides an alternative approach, particularly if drugs with high brain penetration can be identified.